Trial Profile
Single Arm, Two Phase, Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms EECBL
- Sponsors Sinobioway Cell Therapy
- 22 Mar 2017 Status changed from suspended to recruiting.
- 21 Mar 2017 New trial record